Common Supplement Shows Potential in Treating Psoriasis
Pantethine may reduce autoimmune inflammation by regulating cholesterol production in immune cells.
1New Therapeutic Approach Identified
Researchers in Beijing have identified that pantethine, a vitamin B5 derivative, may help treat psoriasis. By calming overactive immune cells, this widely available supplement prevents the development of autoimmune inflammation. The study, published in the Journal of Experimental Medicine, suggests a novel metabolic strategy for managing chronic skin conditions effectively.
2Dendritic Cells and Inflammation
Dendritic cells act as immune system coordinators, identifying threats and triggering inflammatory responses. When these cells become excessively active, they contribute to autoimmune diseases like psoriasis. The research team discovered that these cells rely on specific metabolic pathways, which, when disrupted, lead to the persistent inflammation characteristic of the condition.
3The Role of Vanin Enzymes
Scientists identified high levels of Vanin enzymes in the dendritic cells of psoriasis patients. These enzymes regulate cellular metabolism by converting pantethine into vitamin B5. Excessive Vanin activity depletes internal pantethine levels, which subsequently triggers increased cholesterol production, causing the immune cells to become hyperactive and promote inflammatory damage.
4Cholesterol and Immune Function
The study reveals a critical link between cholesterol metabolism and immune cell behavior. Elevated cholesterol levels within dendritic cells stimulate their activity, exacerbating autoimmune symptoms. By administering pantethine, researchers successfully reduced cholesterol accumulation inside these cells, effectively suppressing the excessive immune activation that drives the progression of psoriasis in mice.
5Human Clinical Trial Results
A small clinical trial involving 24 patients tested pantethine as an adjunctive therapy alongside standard topical ointments. Participants receiving the supplement showed greater symptom improvement over 12 weeks compared to those using only standard treatments. The benefits were particularly pronounced in patients who presented with high blood cholesterol levels before the study.
6Standard Treatment Synergy
All participants in the trial utilized calcipotriene and betamethasone, which are common treatments for controlling skin cell growth and inflammation. The addition of pantethine tablets provided an extra layer of therapeutic efficacy. This suggests that targeting metabolic pathways could enhance the performance of existing standard-of-care treatments for autoimmune skin diseases.
7Study Limitations and Scope
While the results are encouraging, the researchers emphasize that the trial was limited to 24 participants. These findings serve as a proof-of-concept for clinical feasibility rather than direct mechanistic validation in humans. Larger, more comprehensive studies are required to confirm the supplement's effectiveness and establish its safety for broader patient populations.
8Future Research Implications
This discovery highlights the Vanin-pantethine-cholesterol axis as a key pathway governing autoimmune responses. Beyond psoriasis, this metabolic mechanism could potentially be targeted to treat other dendritic cell-mediated diseases. Future research will focus on validating these findings in larger cohorts to determine if metabolic interventions can become a standard medical practice.
Original article: ScienceDaily – Health — Common Supplement Shows Potential in Treating Psoriasis